第61回日本神経学会学術大会

セッション情報

ホットトピックス

[HT-09] ホットトピックス09
Is the concept of embolic stroke of undertermined source (ESUS) dead or alive?

2020年9月1日(火) 10:45 〜 12:15 第01会場 (岡山コンベンションセンター 4F 405会議室)

座長:豊田 一則(国立循環器病研究センター 脳血管内科),北園 孝成(九州大学大学院医学研究院病態機能内科学)

山口 啓二 (一宮西病院 脳神経内科)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.

上野 祐司1, 卜部 貴夫2, 服部 信孝1 (1.順天堂大学医学部附属順天堂医院, 2.順天堂大学医学部附属浦安病院)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.

山上 宏 (国立病院機構大阪医療センター 脳卒中内科)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.

内山 真一郎 (山王病院・山王メディカルセンター 脳血管センター)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.

Hans C. Diener (Faculty of Medicine and Institute for Med-ical Informatics, Biometry and Epidemiol-ogy at the University of Duisburg-Essen)

Two clinical trials to compare direct oral anticoagulants (DOACs) and aspirin did not show superiority of DOACs over aspirin in patients with embolic stroke of undertermined source (ESUS). It is argued on the reasons for the negative results that covert atrial fibrilltion may not be a major cause and arteriogenic embolism may be prevalent than ever thought. In this symposium, we analyze the factors affecting the results, reconsider the the currrent concept of EUS, and perspect future direction of antithrombotic therapy.